Search Results - "Moore, Melvin"

Syndecan-1 facilitates breast cancer metastasis to the brain by Sayyad, Megan R., Puchalapalli, Madhavi, Vergara, Natasha G., Wangensteen, Sierra Mosticone, Moore, Melvin, Mu, Liang, Edwards, Chevaunne, Anderson, Aubree, Kall, Stefanie, Sullivan, Megan, Dozmorov, Mikhail, Singh, Jaime, Idowu, Michael O., Koblinski, Jennifer E.

“…Purpose Although survival rates for patients with localized breast cancer have increased, patients with metastatic breast cancer still have poor prognosis…”
Get full text

Phase III Comparison of Two Irinotecan Dosing Regimens in Second-Line Therapy of Metastatic Colorectal Cancer by FUCHS, Charles S, MOORE, Melvin R, HARKER, Graydon, VILLA, Luis, RINALDI, David, HECHT, J. Randolph

“…Randomized trials in fluorouracil (FU)-refractory colorectal cancer demonstrate significant survival advantages for patients receiving irinotecan. We…”
Get full text

Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens by FOSSELLA, F. V, DEVORE, R, GANDARA, D, KARP, D, VOKES, E, KRIS, M, KIM, Y, GAMZA, F, HAMMERSHAIMB, L, KERR, R. N, CRAWFORD, J, NATALE, R. R, DUNPHY, F, KALMAN, L, MILLER, V, LEE, J. S, MOORE, M

“…PURPOSE: To confirm the promising phase II results of docetaxel monotherapy, this phase III trial was conducted of chemotherapy for patients with advanced…”
Get full text

The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer by Robert, Nicholas J., Vogel, Charles L., Henderson, I. Craig, Sparano, Joseph A., Moore, Melvin R., Silverman, Paula, Overmoyer, Beth A., Shapiro, Charles L., Park, John W., Colbern, Gail T., Winer, Eric P., Gabizon, Alberto A.

“…For patients whose breast cancers are not responsive to endocrine therapy, there are a large number of cytotoxic drugs that will induce a response. In spite of…”
Get full text

A risk scoring system for African-American (AA) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line abiraterone (ABA) or enzalutamide (ENZ) by Brown, Jacqueline T, Liu, Yuan, LaFollette, Jennifer Ann, Kucuk, Omer, Moore, Melvin R., Bilen, Mehmet Asim

“…Abstract only 51 Background: AA pts represented < 3% of the COU-AA-302 and PREVAIL trial cohorts that led to the approval of ABA and ENZ in the 1st line…”
Get full text

Clinical Outcomes and Racial Disparities in Metastatic Hormone‐Sensitive Prostate Cancer in the Era of Novel Treatment Options by Smith, Katherine Emilie Rhoades, Brown, Jacqueline Theresa, Wan, Limeng, Liu, Yuan, Russler, Greta, Yantorni, Lauren, Caulfield, Sarah, Lafollette, Jennifer, Moore, Melvin, Kucuk, Omer, Carthon, Bradley, Nazha, Bassel, Bilen, Mehmet Asim

“…Background Docetaxel (DOC) and abiraterone (ABI) in the upfront setting have separately improved clinical outcomes for metastatic hormone‐sensitive prostate…”
Get full text

The real-world efficacy of abiraterone acetate (ABA) and docetaxel (DOC) in the treatment of African-American (AA) patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) by Smith, Katherine E.R., Brown, Jacqueline T, Liu, Yuan, LaFollette, Jennifer Ann, Moore, Melvin R., Bilen, Mehmet Asim

“…Abstract only 52 Background: The landscape of mCSPC treatment changed with the addition of ABA and DOC. The prevalence of AA pts in the trials that led to…”
Get full text

A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188) by GRADISHAR, William J, STEPHENSON, Patricia, GLOVER, Donna J, NEUBERG, Donna S, MOORE, Melvin R, WINDSCHITL, Harold E, PIEL, Ira, ABELOFF, Martin D

“…Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma. Older reports suggest an objective…”
Get full text

Baseline basophil and basophil-to-lymphocyte status is associated with clinical outcomes in metastatic hormone sensitive prostate cancer by Hadadi, Agreen, Smith, Katherine ER, Wan, Limeng, Brown, Jacqueline R, Russler, Greta, Yantorni, Lauren, Caulfield, Sarah, Lafollette, Jennifer, Moore, Melvin, Kucuk, Omer, Carthon, Bradley, Nazha, Bassel, Liu, Yuan, Bilen, Mehmet A

“…•We found that metastatic hormone sensitive prostate cancer patients with high baseline basophils and basophil-to-lymphocyte ratios (BLR) had worse…”
Get full text

A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX‐710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer by Gandhi, Leena, Harding, Matthew W., Neubauer, Marcus, Langer, Corey J., Moore, Melvin, Ross, Helen J., Johnson, Bruce E., Lynch, Thomas J.

“…BACKGROUND. Tumors with multidrug resistance (MDR) frequently up‐regulate efflux proteins, including MDR‐associated protein (MRP‐1) and P‐glycoprotein (Pgp)…”
Get full text

Discordance in Monogamy Beliefs, Sexual Concurrency, and Condom Use Among Young Adult Substance-Involved Couples: Implications for Risk of Sexually Transmitted Infections by RIEHMAN, KARA S., WECHSBERG, WENDEE M., FRANCIS, SHELLEY A., MOORE, MELVIN, MORGAN-LOPEZ, ANTONIO

“…Objectives and Goal: The objectives of this study were to examine the association between individual and partnership characteristics with condom use, sexual…”
Get full text

A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia by Saleh, M N, Gutheil, J, Moore, M, Bunch, P W, Butler, J, Kunkel, L, Grillo-López, A J, LoBuglio, A F

“…We conducted a prospective pilot phase I/II clinical trial to evaluate the toxicity and response rate of the chimeric anti-CD20 monoclonal antibody, rituximab…”
Get more information

Bone Pain Associated with Once-Per-Cycle Pegfilgrastim Is Similar to Daily Filgrastim in Patients with Breast Cancer by Kubista, Ernst, Glaspy, John, Ann Holmes, Frankie, Green, Michael D., Hackett, James, Neumann, Theresa

“…Bone pain is a common side effect of treatment with filgrastim. Pegfilgrastim is a pegylated long-acting analogue of filgrastim that is administered once per…”
Get full text

Characterization of postsplenectomy bacteremia among patients with and without lymphoma by Donaldson, S S, Moore, M R, Rosenberg, S A, Vosti, K L

Get more information

Approach to the management of pleural effusion in malignancy by Sarma, P R, Moore, M R

“…The diagnostic and therapeutic approaches to malignant pleural effusions are reviewed, and data on the retrospective study of 37 patients are presented with…”
Get more information

The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer: Established and emerging roles of liposomal anthracyclines in oncology by ROBERT, Nicholas J, VOGEL, Charles L, WINER, Eric P, GABIZON, Alberto A, HENDERSON, I. Craig, SPARANO, Joseph A, MOORE, Melvin R, SILVERMAN, Paula, OVERMOYER, Beth A, SHAPIRO, Charles L, PARK, John W, COLBERN, Gail T

Get full text

A Phase II trial of cisplatin plus WR‐2721 (amifostine) for metastatic breast carcinoma by Gradishar, William J., Stephenson, Patricia, Glover, Donna J., Neuberg, Donna S., Moore, Melvin R., Windschitl, Harold E., Piel, Ira, Abeloff, Martin D.

“…BACKGROUND Cisplatin has minimal antitumor activity when used as second‐ or third‐line treatment of metastatic breast carcinoma. Older reports suggest an…”
Get full text

The Use of Controlled-Release Oxycodone for the Treatment of Chronic Cancer Pain: A Randomized, Double-Blind Study by Parris, Winston C.-V., Johnson, Benjamin W., Croghan, Marilyn K., Moore, Melvin R., Khojasteh, Ali, Reder, Robert F., Kaiko, Robert F., Buckley, Barbara J.

“…To compare the effectiveness and safety of controlled-release (CR) oxycodone tablets with immediate-release (IR) oxycodone in patients with chronic cancer…”
Get full text

Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care by Holland, H K, Dix, S P, Geller, R B, Devine, S M, Heffner, L T, Connaghan, D G, Hillyer, C D, Hughes, L L, Miller, R L, Moore, M R, Winton, E F, Wingard, J R

“…To assess the clinical toxicity and outcome associated with a comprehensive supportive care approach in poor-risk breast cancer (BrCA) patients with high-dose…”
Get more information

Combination chemotherapy and radiotherapy for Hodgkin's disease by Rosenberg, S A, Moore, M R, Bull, J M, Jones, S E, Kaplan, H S

Get more information